Cargando…

Evidence for histidine-rich protein 2 immune complex formation in symptomatic patients in Southern Zambia

BACKGROUND: Rapid diagnostic tests based on histidine-rich protein 2 (HRP2) detection are the primary tools used to detect Plasmodium falciparum malaria infections. Recent conflicting reports call into question whether α-HRP2 antibodies are present in human host circulation and if resulting immune c...

Descripción completa

Detalles Bibliográficos
Autores principales: Markwalter, Christine F., Mudenda, Lwiindi, Leelawong, Mindy, Kimmel, Danielle W., Nourani, Armin, Mbambara, Saidon, Thuma, Philip E., Wright, David W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6038308/
https://www.ncbi.nlm.nih.gov/pubmed/29986725
http://dx.doi.org/10.1186/s12936-018-2400-8
_version_ 1783338473934028800
author Markwalter, Christine F.
Mudenda, Lwiindi
Leelawong, Mindy
Kimmel, Danielle W.
Nourani, Armin
Mbambara, Saidon
Thuma, Philip E.
Wright, David W.
author_facet Markwalter, Christine F.
Mudenda, Lwiindi
Leelawong, Mindy
Kimmel, Danielle W.
Nourani, Armin
Mbambara, Saidon
Thuma, Philip E.
Wright, David W.
author_sort Markwalter, Christine F.
collection PubMed
description BACKGROUND: Rapid diagnostic tests based on histidine-rich protein 2 (HRP2) detection are the primary tools used to detect Plasmodium falciparum malaria infections. Recent conflicting reports call into question whether α-HRP2 antibodies are present in human host circulation and if resulting immune complexes could interfere with HRP2 detection on malaria RDTs. This study sought to determine the prevalence of immune-complexed HRP2 in a low-transmission region of Southern Zambia. METHODS: An ELISA was used to quantify HRP2 in patient sample DBS extracts before and after heat-based immune complex dissociation. A pull-down assay reliant on proteins A, G, and L was developed and applied for IgG and IgM capture and subsequent immunoprecipitation of any HRP2 present in immune complexed form. A total of 104 patient samples were evaluated using both methods. RESULTS: Immune-complexed HRP2 was detectable in 17% (18/104) of all samples evaluated and 70% (16/23) of HRP2-positive samples. A majority of the patients with samples containing immune-complexed HRP2 had P. falciparum infections (11/18) and were also positive for free HRP2 (16/18). For 72% (13/18) of patients with immune-complexed HRP2, less than 10% of the total HRP2 present was in immune-complexed form. For the remaining samples, a large proportion (≥ 20%) of total HRP2 was complexed with α-HRP2 antibodies. CONCLUSIONS: Endogenous α-HRP2 antibodies form immune complexes with HRP2 in the symptomatic patient population of a low-transmission area in rural Southern Zambia. For the majority of patients, the percentage of HRP2 in immune complexes is low and does not affect HRP2-based malaria diagnosis. However, for some patients, a significant portion of the total HRP2 was in immune-complexed form. Future studies investigating the prevalence and proportion of immune-complexed HRP2 in asymptomatic individuals with low HRP2 levels will be required to assess whether α-HRP2 antibodies affect HRP2 detection for this portion of the transmission reservoir. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12936-018-2400-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6038308
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-60383082018-07-12 Evidence for histidine-rich protein 2 immune complex formation in symptomatic patients in Southern Zambia Markwalter, Christine F. Mudenda, Lwiindi Leelawong, Mindy Kimmel, Danielle W. Nourani, Armin Mbambara, Saidon Thuma, Philip E. Wright, David W. Malar J Research BACKGROUND: Rapid diagnostic tests based on histidine-rich protein 2 (HRP2) detection are the primary tools used to detect Plasmodium falciparum malaria infections. Recent conflicting reports call into question whether α-HRP2 antibodies are present in human host circulation and if resulting immune complexes could interfere with HRP2 detection on malaria RDTs. This study sought to determine the prevalence of immune-complexed HRP2 in a low-transmission region of Southern Zambia. METHODS: An ELISA was used to quantify HRP2 in patient sample DBS extracts before and after heat-based immune complex dissociation. A pull-down assay reliant on proteins A, G, and L was developed and applied for IgG and IgM capture and subsequent immunoprecipitation of any HRP2 present in immune complexed form. A total of 104 patient samples were evaluated using both methods. RESULTS: Immune-complexed HRP2 was detectable in 17% (18/104) of all samples evaluated and 70% (16/23) of HRP2-positive samples. A majority of the patients with samples containing immune-complexed HRP2 had P. falciparum infections (11/18) and were also positive for free HRP2 (16/18). For 72% (13/18) of patients with immune-complexed HRP2, less than 10% of the total HRP2 present was in immune-complexed form. For the remaining samples, a large proportion (≥ 20%) of total HRP2 was complexed with α-HRP2 antibodies. CONCLUSIONS: Endogenous α-HRP2 antibodies form immune complexes with HRP2 in the symptomatic patient population of a low-transmission area in rural Southern Zambia. For the majority of patients, the percentage of HRP2 in immune complexes is low and does not affect HRP2-based malaria diagnosis. However, for some patients, a significant portion of the total HRP2 was in immune-complexed form. Future studies investigating the prevalence and proportion of immune-complexed HRP2 in asymptomatic individuals with low HRP2 levels will be required to assess whether α-HRP2 antibodies affect HRP2 detection for this portion of the transmission reservoir. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12936-018-2400-8) contains supplementary material, which is available to authorized users. BioMed Central 2018-07-09 /pmc/articles/PMC6038308/ /pubmed/29986725 http://dx.doi.org/10.1186/s12936-018-2400-8 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Markwalter, Christine F.
Mudenda, Lwiindi
Leelawong, Mindy
Kimmel, Danielle W.
Nourani, Armin
Mbambara, Saidon
Thuma, Philip E.
Wright, David W.
Evidence for histidine-rich protein 2 immune complex formation in symptomatic patients in Southern Zambia
title Evidence for histidine-rich protein 2 immune complex formation in symptomatic patients in Southern Zambia
title_full Evidence for histidine-rich protein 2 immune complex formation in symptomatic patients in Southern Zambia
title_fullStr Evidence for histidine-rich protein 2 immune complex formation in symptomatic patients in Southern Zambia
title_full_unstemmed Evidence for histidine-rich protein 2 immune complex formation in symptomatic patients in Southern Zambia
title_short Evidence for histidine-rich protein 2 immune complex formation in symptomatic patients in Southern Zambia
title_sort evidence for histidine-rich protein 2 immune complex formation in symptomatic patients in southern zambia
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6038308/
https://www.ncbi.nlm.nih.gov/pubmed/29986725
http://dx.doi.org/10.1186/s12936-018-2400-8
work_keys_str_mv AT markwalterchristinef evidenceforhistidinerichprotein2immunecomplexformationinsymptomaticpatientsinsouthernzambia
AT mudendalwiindi evidenceforhistidinerichprotein2immunecomplexformationinsymptomaticpatientsinsouthernzambia
AT leelawongmindy evidenceforhistidinerichprotein2immunecomplexformationinsymptomaticpatientsinsouthernzambia
AT kimmeldaniellew evidenceforhistidinerichprotein2immunecomplexformationinsymptomaticpatientsinsouthernzambia
AT nouraniarmin evidenceforhistidinerichprotein2immunecomplexformationinsymptomaticpatientsinsouthernzambia
AT mbambarasaidon evidenceforhistidinerichprotein2immunecomplexformationinsymptomaticpatientsinsouthernzambia
AT thumaphilipe evidenceforhistidinerichprotein2immunecomplexformationinsymptomaticpatientsinsouthernzambia
AT wrightdavidw evidenceforhistidinerichprotein2immunecomplexformationinsymptomaticpatientsinsouthernzambia